Mainstay Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Mainstay Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-26,140	Closed	-$633K	–	104
2022 Q1	$633K	Buy	26,140 +183	+0.7%	+$4.43K	0.12%	69
2021 Q4	$606K	Sell	25,957 -6,073	-19%	-$122K	0.18%	76
2021 Q3	$532K	Buy	32,030 +4,665	+17%	+$89.9K	0.3%	67
2021 Q2	$667K	Sell	27,365 -200	-0.7%	-$4.51K	0.16%	77
2021 Q1	$711K	Sell	27,565 -1,990	-7%	-$87.6K	0.22%	76
2020 Q4	$1.58M	Sell	29,555 -145	-0.5%	-$7.2K	0.46%	35
2020 Q3	$1.23M	Sell	29,700 -3,270	-10%	-$141K	0.32%	47
2020 Q2	$1.6M	Buy	32,970 +160	+0.5%	+$7.68K	0.47%	32
2020 Q1	$1.33M	Sell	32,810 -945	-3%	-$38.9K	0.43%	28
2019 Q4	$1.44M	Buy	+33,755	New	+$1.47M	0.33%	52

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mainstay Capital Management's ACAD Position: Q2 2022 in Review

Mainstay Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 26,140 shares — an estimated $633K sold.

Mainstay Capital Management first reported a position in ACAD in Q4 2019 and held it in 10 quarters. The position peaked at $1.6M in Q2 2020. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

Mainstay Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Mainstay Capital Management sold 26,140 Acadia Pharmaceuticals shares in Q2 2022, an estimated $633K.
Mainstay Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Mainstay Capital Management's Acadia Pharmaceuticals position peaked at $1.6M in Q2 2020.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Mainstay Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.